Zoledronic acid reduces the survival-adjusted cumulative incidence of radiotherapy to bone in patients with bone metastases from breast or prostate cancer
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- January 1, 2004
has subject area
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Annals of Oncology Journal